Warning! GuruFocus detected
5 Severe warning signs
with OCX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
OncoCyte Corp
NAICS : 541380
SIC : 8734
ISIN : US68235C1071
Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.84 | |||||
| Equity-to-Asset | 0.14 | |||||
| Debt-to-Equity | 0.41 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -7.47 | |||||
| Beneish M-Score | -5.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -19.2 | |||||
| 3-Year EBITDA Growth Rate | 31.3 | |||||
| 3-Year EPS without NRI Growth Rate | 34 | |||||
| 3-Year FCF Growth Rate | 28.1 | |||||
| 3-Year Book Growth Rate | -36.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 25.37 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.25 | |||||
| 9-Day RSI | 50.23 | |||||
| 14-Day RSI | 55.72 | |||||
| 3-1 Month Momentum % | 21 | |||||
| 6-1 Month Momentum % | -20.66 | |||||
| 12-1 Month Momentum % | -13.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.53 | |||||
| Quick Ratio | 0.5 | |||||
| Cash Ratio | 0.37 | |||||
| Days Inventory | 102.77 | |||||
| Days Sales Outstanding | 290.46 | |||||
| Days Payable | 435.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -33.7 | |||||
| Shareholder Yield % | -0.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -16.22 | |||||
| Operating Margin % | -3226.94 | |||||
| Net Margin % | -6085.19 | |||||
| FCF Margin % | -2832.86 | |||||
| ROE % | -211.42 | |||||
| ROA % | -57.93 | |||||
| ROIC % | -32.75 | |||||
| 3-Year ROIIC % | 60.68 | |||||
| ROC (Joel Greenblatt) % | -731.88 | |||||
| ROCE % | -64.77 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 44 | |||||
| PB Ratio | 4.66 | |||||
| EV-to-EBIT | -2.21 | |||||
| EV-to-EBITDA | -2.28 | |||||
| EV-to-Revenue | 134 | |||||
| EV-to-Forward-Revenue | 9.99 | |||||
| EV-to-FCF | -4.73 | |||||
| Earnings Yield (Greenblatt) % | -45.25 | |||||
| FCF Yield % | -20.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OCX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OncoCyte Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.709 | ||
| EPS (TTM) ($) | -4.54 | ||
| Beta | 1.27 | ||
| 3-Year Sharpe Ratio | -0.86 | ||
| 3-Year Sortino Ratio | -1.17 | ||
| Volatility % | 50.59 | ||
| 14-Day RSI | 55.72 | ||
| 14-Day ATR ($) | 0.394108 | ||
| 20-Day SMA ($) | 3.37184 | ||
| 12-1 Month Momentum % | -13.11 | ||
| 52-Week Range ($) | 1.922 - 4.75 | ||
| Shares Outstanding (Mil) | 28.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OncoCyte Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OncoCyte Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
OncoCyte Corp Frequently Asked Questions
What is OncoCyte Corp(OCX)'s stock price today?
The current price of OCX is $3.43. The 52 week high of OCX is $4.75 and 52 week low is $1.92.
When is next earnings date of OncoCyte Corp(OCX)?
The next earnings date of OncoCyte Corp(OCX) is 2025-03-24.
Does OncoCyte Corp(OCX) pay dividends? If so, how much?
OncoCyte Corp(OCX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers